exv10w1



 






AMENDMENT

TO THE

FINISHED PRODUCT SUPPLY AGREEMENT



This Amendment (the “Amendment”) is made and entered into as of August 26, 2005 by and
between Janssen Pharmaceutica, NV, a business corporation organized under the Laws of Belgium,
having its principal office at B-2340 Beerse, Turnhoutseweg 30, Belgium (hereinafter referred to as
“Janssen”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600
College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as
“Barrier”).



WHEREAS, Janssen and Barrier are parties to that certain Finished Product Supply Agreement dated
July 14, 2004 (the “Original Agreement”); and



WHEREAS, Janssen and Barrier desire to make certain amendments to the Original Agreement pursuant
to the terms of this Amendment.



NOW, THEREFORE, in consideration of the above premises and the covenants contained herein, the
parties agree as follows:



1. The Original Agreement is hereby amended as follows:





	 	1.1.	 	Section 3.2 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“The Price ex-works for the Finished Product shall be: tube of 60 gram: € 1.00 (one
Euro) per unit.”
	 
	 	1.2.	 	Section 4.1 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“BARRIER commits to purchase a total of 1,000,000 (one million) 60 gram tubes prior
to June 30, 2008.
	 
	 	 	 	In case this Agreement is terminated for whatever reason except breach of contract
by JANSSEN but including without limitation termination under Article 10.3 below,
and BARRIER has not yet purchased and paid a minimum of 1,000,000 (one million) 60
gram tubes on the effective date of termination, BARRIER shall pay to JANSSEN a
penalty equal to of 0.50 Euro (one half Euro) multiplied by the number of 60 gram
tubes that BARRIER has failed to buy and pay compared to the 1,000,000 (one
million) 60 gram tubes minimum.”




 









 






	 	1.3.	 	Section 10.3 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“JANSSEN shall be entitled, but not obligated, to terminate this Agreement at any
time, by way of written notice if, after June 30, 2008, BARRIER has not yet bought
and paid a total of 1,000,000 (1 million) 60 gram tubes of Finished Product”
	 
	 	1.4.	 	The references to “30 gram tubes” in each of Sections 9.1 and on Exhibit I
are hereby amended to read as “60 gram tubes.”
	 
	 	1.5.	 	Section 4.4 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“The following minimum quantities of the Finished Product to be ordered with each
order shall apply: 45,000 (forty-five thousand) 60 gram tubes or a multiple
thereof.”




2. Capitalized terms used herein and not otherwise defined shall have the meanings given to them in
the Original Agreement.



3. Except as expressly amended herein, all terms and conditions of the Original Agreement shall
remain in full force and effect.



4. This Amendment shall in all respects, be subject to substantive Belgian law except that the
Parties explicitly waive the application of the law of July 27, 1961 (as amended).



5. This Amendment may be executed in one or more counterparts, each of which shall for all purposes
be deemed to be an original and all of which shall constitute the same instrument. This Amendment
may be executed by facsimile signature which shall have the same force and effect as the original
signatures.




[ Signatures to Follow ]




2









 








     IN WITNESS WHEREOF, and intending to be legally bound, the parties hereto have caused this
Amendment to be executed by their duly authorized representatives as of the date first set forth
above.



	 	 	 	 	 
	JANSSEN PHARMACEUTICA, NV	 	 
	 
	 	 	 	 
	By:

	 	   RENE HEX
 

	 	 
	Name: Rene Hex	 	 
	Title: CFO & Vice President Finance	 	 
	 
	 	 	 	 
	BARRIER THERAPEUTICS, INC.	 	 
	 
	 	 	 	 
	By:

	 	   AL ALTOMARI
 

	 	 
	Name: Al Altomari	 	 
	Title: Chief Commercial Officer	 	 







3